person · Reporting owner
Kelsey Stephen Michael
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jiya Acquisition Corp.JYAC · Entity 123583 | Director | November 18, 2020 | November 19, 2020 |
| Revolution Medicines, Inc.RVMD · Entity 606 | See Remarks | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jiya Acquisition Corp.
Report date November 18, 2020 · Filed November 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.
F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 291,791 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 85 · Balance 291,791 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 286,307 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 5,484 · Balance 286,307 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 65,613 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 65,613 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2024 Filed Aug 15, 2024 20:48 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 16,667 | $42.98 | $716,389.33 |
DisclosureSEC source: 0001610717-24-000427 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,073 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F3 · price: The transaction was executed in multiple trades in prices ranging from $42.76 to $43.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:48 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 16,667 | $4.09 | $68,168.03 |
DisclosureSEC source: 0001610717-24-000427 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000398 · form4.xml · derivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,332 Underlying: Common Stock · 16,667 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,879 | $48.06 | $186,420.47 |
DisclosureSEC source: 0001610717-24-000398 · form4.xml · nonDerivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,073 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F7 · price: The transaction was executed in multiple trades in prices ranging from $47.62 to $48.47, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,800 | $47.02 | $178,683.22 |
DisclosureSEC source: 0001610717-24-000398 · form4.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272,952 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F6 · price: The transaction was executed in multiple trades in prices ranging from $46.62 to $47.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,760 | $46.08 | $265,406.40 |
DisclosureSEC source: 0001610717-24-000398 · form4.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,752 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F5 · price: The transaction was executed in multiple trades in prices ranging from $45.60 to $46.53, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,128 | $44.94 | $95,622.32 |
DisclosureSEC source: 0001610717-24-000398 · form4.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,512 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F4 · price: The transaction was executed in multiple trades in prices ranging from $44.40 to $45.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,100 | $43.99 | $48,384.05 |
DisclosureSEC source: 0001610717-24-000398 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,640 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F3 · price: The transaction was executed in multiple trades in prices ranging from $43.37 to $44.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 16,667 | $4.09 | $68,168.03 |
DisclosureSEC source: 0001610717-24-000398 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,467 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000364 · form4.xml · derivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,999 Underlying: Common Stock · 16,467 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 16,467 | $39.06 | $643,151.62 |
DisclosureSEC source: 0001610717-24-000364 · form4.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,073 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F3 · price: The transaction was executed in multiple trades in prices ranging from $39.00 to $39.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 16,467 | $4.09 | $67,350.03 |
DisclosureSEC source: 0001610717-24-000364 · form4.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000364 · form4.xml · derivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,466 Underlying: Common Stock · 200 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 200 | $39.00 | $7,800.00 |
DisclosureSEC source: 0001610717-24-000364 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,073 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 200 | $4.09 | $818.00 |
DisclosureSEC source: 0001610717-24-000364 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,349 | $37.39 | $125,209.06 |
DisclosureSEC source: 0001610717-24-000349 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,073 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $37.3867 to $37.3887, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024. F4 · balance_after: Includes 95,476 RSUs. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:45 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,123 | $31.58 | $67,051.13 |
DisclosureSEC source: 0001610717-24-000173 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,909 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · balance_after: Includes 104,550 RSUs. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:54 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 179,900 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001610717-24-000131 · form4.xml · derivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,900 Underlying: Common Stock · 179,900 shares Expires 2034-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:54 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 51,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000131 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,032 F1 · balance_after: Includes 110,413 restricted stock units. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,337 | $29.01 | $96,809.04 |
DisclosureSEC source: 0001610717-24-000025 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,632 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 59,013 restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 13,330 | $29.10 | $387,884.34 |
DisclosureSEC source: 0001610717-24-000008 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,969 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 59,013 restricted stock units. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 33,334 | $29.01 | $966,996.01 |
DisclosureSEC source: 0001610717-23-000425 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,299 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 59,013 restricted stock units. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,088 | $25.90 | $54,082.54 |
DisclosureSEC source: 0001610717-23-000413 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,633 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: The transaction was executed in multiple trades in prices ranging from $25.8901 to $25.909, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · balance_after: Includes 59,013 RSUs. Read SEC document |
| October 11, 2023 Filed Oct 13, 2023 20:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 16,667 | $29.05 | $484,129.68 |
DisclosureSEC source: 0001610717-23-000309 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 273,721 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 64,875 restricted stock units. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:13 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,060 | $31.31 | $64,499.84 |
DisclosureSEC source: 0001610717-23-000295 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,388 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: The transaction was executed in multiple trades in prices ranging from $31.1033 to $31.3108, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 64,875 RSUs. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 20:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 16,666 | $32.40 | $539,978.40 |
DisclosureSEC source: 0001610717-23-000221 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,448 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022. F3 · balance_after: Includes 70,738 restricted stock units. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 16,666 | $29.19 | $486,502.21 |
DisclosureSEC source: 0001610717-23-000221 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,114 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 70,738 restricted stock units. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,102 | $24.89 | $52,320.88 |
DisclosureSEC source: 0001610717-23-000195 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,780 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. F3 · balance_after: Includes 70,738 RSUs. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:33 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,230 | $21.78 | $26,789.40 |
DisclosureSEC source: 0000899243-23-009375 · doc4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,369 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.4115 to $21.784581, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 76,600 RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001567619-23-004353 · doc1.xml · derivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004353 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,599 F1 · balance_after: Includes 79,963 restricted stock units. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,220 | $22.94 | $27,985.70 |
DisclosureSEC source: 0001567619-22-021927 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,599 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $22.47 to $22.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 39,963 RSUs. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:18 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,267 | $19.04 | $24,126.97 |
DisclosureSEC source: 0001567619-22-017691 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,819 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.9729 to $19.0337, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 43,325 RSUs. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,145 | $17.75 | $20,323.18 |
DisclosureSEC source: 0001567619-22-013252 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,086 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 937 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022. F3 · balance_after: Includes 46,688 RSUs. Read SEC document |
| March 17, 2022 Filed Mar 22, 2022 00:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 321 | $18.62 | $5,975.80 |
DisclosureSEC source: 0001567619-22-007326 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,294 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.32 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 50,050 RSUs. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:27 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 135,800 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001567619-22-006236 · doc1.xml · derivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,800 Underlying: Common Stock · 135,800 shares Expires 2032-02-29 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:27 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 38,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006236 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,615 F1 · balance_after: Includes 50,988 Restricted Stock Units. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 343 | $24.41 | $8,372.63 |
DisclosureSEC source: 0001567619-21-022402 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,815 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 12,188 RSUs. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 23:48 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 335 | $30.02 | $10,056.70 |
DisclosureSEC source: 0001567619-21-017416 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,158 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 13,125 RSUs. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:18 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 324 | $34.12 | $11,056.01 |
DisclosureSEC source: 0001567619-21-012490 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,493 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $33.60 to $34.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021. F4 · balance_after: Includes 14,063 RSUs. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:42 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001567619-21-005848 · doc1.xml · derivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2031-03-03 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 4, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:42 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005848 · doc1.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,073 F1 · balance_after: Includes 15,000 Restricted Stock Units. F2 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,248 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · derivative · entry 9 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,055 Underlying: Common Stock · 17,248 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 17,248 | $34.33 | $592,060.02 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · nonDerivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,329 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $34.02 to $34.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 17,248 | $4.73 | $81,583.04 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,268 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · derivative · entry 8 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,303 Underlying: Common Stock · 13,268 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 13,268 | $34.14 | $452,913.79 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,329 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.4550, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 13,268 | $4.73 | $62,757.64 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,384 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · derivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,571 Underlying: Common Stock · 9,384 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 00:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 9,384 | $34.08 | $319,831.12 |
DisclosureSEC source: 0001567619-20-017291 · doc1.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,329 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.